LAUSR

About LAUSR
Donate
Contact Us

Follow us:

You are not signed in:

Sign Up!


   Articles with "non v600" as a keyword



Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations

Sign Up to like & get
recommendations! Published in 2018 at "Oncogene"

DOI: 10.1038/s41388-018-0171-x

Abstract: The RAS–RAF–MEK–ERK signaling cascade is among the most frequently mutated pathways in human cancer. Approximately 50% of melanoma patients possess a druggable hotspot V600E/K mutation in the BRAF protein kinase. FDA-approved combination therapies of BRAF… read more here.

Keywords: braf alterations; braf; cancer; non v600 ... See more keywords

Trametinib Activity in Patients with Solid Tumors and Lymphomas Harboring BRAF Non-V600 Mutations or Fusions: Results from NCI-MATCH (EAY131)

Sign Up to like & get
recommendations! Published in 2020 at "Clinical Cancer Research"

DOI: 10.1158/1078-0432.ccr-19-3443

Abstract: Purpose: Substantial preclinical evidence and case reports suggest that MEK inhibition is an active approach in tumors with BRAF mutations outside the V600 locus, and in BRAF fusions. Thus, Subprotocol R of the NCI-MATCH study… read more here.

Keywords: braf; solid tumors; non v600; nci match ... See more keywords

Non-V600 BRAF mutations in advanced malignancies: Prevalence and survival impact.

Sign Up to like & get
recommendations! Published in 2018 at "Journal of Clinical Oncology"

DOI: 10.1200/jco.2018.36.15_suppl.12100

Abstract: 12100Background: BRAF mutations that occur outside of codon 600, non-V600 BRAF (non-V600BRAF), have been detected in various types of tumors. Prevalence, and prognostic impact remain underestimated... read more here.

Keywords: v600 braf; non v600; impact; braf mutations ... See more keywords

Targeting rare variants of a pan-cancer target: The landscape of BRAF non-v600 mutations and BRAFfusions from 172,005 adult patients with cancer.

Sign Up to like & get
recommendations! Published in 2024 at "Journal of Clinical Oncology"

DOI: 10.1200/jco.2024.42.16_suppl.3113

Abstract: 3113 Background: BRAF is a recognized pan-cancer target, with dabrafenib in combination with trametinib receiving FDA accelerated approval for unresectable metastatic solid tumors with BRAF V600E mutation. BRAF fusions and mutations at codons aside from… read more here.

Keywords: non v600; cancer; braf fusions; braf ... See more keywords

Exploring the efficacy and mechanism of action of combined pan-Raf and MEK inhibition in halting the growth of non-V600 BRAF mutated tumors.

Sign Up to like & get
recommendations! Published in 2025 at "Journal of Clinical Oncology"

DOI: 10.1200/jco.2025.43.16_suppl.3117

Abstract: 3117 Background: Class 2 & 3 non-V600 BRAF mutations mediate RAF dimerization to hyperactivate the MAPK signaling pathway. Encorafenib (Enco; BRAF monomer inhibitor) + Binimetinib (Bini; MEK inhibitor) elicit responses in 10) vs. Enco+Bini that… read more here.

Keywords: v600 braf; braf; non v600; belva bini ... See more keywords

Clinical, Pathological and Prognostic Features of Rare BRAF Mutations in Metastatic Colorectal Cancer (mCRC): A Bi-Institutional Retrospective Analysis (REBUS Study)

Sign Up to like & get
recommendations! Published in 2021 at "Cancers"

DOI: 10.3390/cancers13092098

Abstract: Simple Summary Somatic BRAF mutations occur in approximately 10% of metastatic colorectal cancers (mCRCs) and, according to the involved codon, are classified as V600E and in non-V600, accounting for 80% and 20%, respectively. Being the… read more here.

Keywords: mcrcs; non v600; braf non; braf ... See more keywords

Genomic Landscape, Clinical Features and Outcomes of Non-Small Cell Lung Cancer Patients Harboring BRAF Alterations of Distinct Functional Classes

Sign Up to like & get
recommendations! Published in 2022 at "Cancers"

DOI: 10.3390/cancers14143472

Abstract: Simple Summary Non-small cell lung cancer (NSCLC) patients harboring BRAF non-V600 alterations constitute a heterogeneous and poorly studied population orphan of targeted therapies. We conducted a systematic review to detect all BRAF alterations of defined… read more here.

Keywords: cancer; braf alterations; nsclc patients; class ... See more keywords

Oncogenic non-V600 mutations evade the regulatory machinery of RAF including the Cdc37/Hsp90 chaperone and the 14-3-3 scaffold

Sign Up to like & get
recommendations! Published in 2025 at "Theranostics"

DOI: 10.7150/thno.103958

Abstract: The Ser/Thr kinase RAF, particularly BRAF isoform is a dominant target of oncogenic mutations and many mutations have been identified in various cancers. However, how these mutations except V600E evade the regulatory machinery of RAF… read more here.

Keywords: regulatory machinery; non v600; cdc37 hsp90; v600 mutations ... See more keywords